The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer
Biochemically recurrent prostate cancer represents a stage of prostate cancer where conventional (continued on next page) computed tomography and technetium Tc 99m bone scan imaging are unable to detect disease after curative intervention despite rising prostate-specific antigen. There is no clear standard of care and no systemic therapy has been shown to improve survival. Immunotherapy-based treatments potentially are attractive options relative to androgen deprivation therapy due to the generally more favorable side-effect profile. Biochemically recurrent prostate cancer patients have a low tumor burden and likely lymph node-based disease, which may make them more likely to respond to immunotherapy.
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: Marijo Bilusic, David J. Einstein, Fatima H. Karzai, William L. Dahut, James L. Gulley, Jeanny B. Aragon-Ching, Ravi A. Madan Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Immunotherapy | PET Scan | Prostate Cancer | Urology & Nephrology